Novo Nordisk launches first GLP-1 pill for obesity, but Lilly may dominate the oral market eventually

GLP-1 drugs have become the hottest drug class in a generation, driven by an obesity epidemic affecting 40% of American adults and linked to diabetes, heart disease and a growing list of other conditions. But there’s a catch: up to two-thirds of adults report some level of needle fear. A 2022 PLOS One international survey… The post Novo Nordisk launches first GLP-1 pill for obesity, but Lilly may dominate the oral market eventually appeared first on Drug Discovery and Development.

Continue reading →